Glycolipid mimetics with selective anti or pro-inflammatory response

Patent number:

EP21382980, EP21382981

No items found.

Novel glycolipid mimetics have been identified that are able to express anti inflammatory or adjuvant activity in a context dependent manner The compounds can be used for the treatment of immune diseases cursed with Th 1 /Th 2 imbalance or as vaccine adjuvants

Countries:

Spain

Regions:

Andalusia

Centers:

CSIC

Other entities:

Sectors:

Health

Subsectors:

Pharmaceuticals

TRL Level:

TRL 3 – experimental proof of concept

BRL Level:

PDF Link:

Download here

Video Link:

Watch it here

Sustainable Development Goal:

Applications

Los compuestos selectivos han mostrado supresión de la inflamación inducida por α-GalCer o LPS in vitro e in vivo. Algunos compuestos fueron competentes para inducir una respuesta sesgada hacia Th1 y otros hacia Th2. Capacidad de suprimir la inflamación Th2 confirmada in vivo en un modelo de hiperreactividad de las vías respiratorias inducida por ovoalbúmina (OVA) en ratones. Capacidad adyuvante de algunos compuestos demostrada in vivo.

Comments

Other related patents

Health

DEVICE AND METHOD FOR STEREOLITHOGRAPHIC THREE DIMENSIONAL PRINTING

Countries

Spain

Health

New & Sustainable Materials

Automotive & Rail

Textile

A woven fabric comprising thermoplastic polymer filaments from non-shape memory polymers and filaments from shape memory polymers and uses thereof

Countries

Spain

Health

POLYCERASOIDOL AND POLYCERASOIDIN DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES, TYPE 2 DIABETES MELLITUS, HYPERCHOLESTEROLEMIA, DYSLIPIDEMIAS AND ATHEROSCLEROSIS.

Countries

Spain

Get back to patents directory